Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Vertex Pharmaceuticals. The associated price target remains the same with $598.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tazeen Ahmad has given his Buy rating due to a combination of factors, including solid growth in Vertex’s core cystic fibrosis portfolio and a favorable revenue outlook. She highlights that Trikafta and Alyftrek remain key drivers, with Alyftrek increasingly adopted as the preferred CF therapy and company guidance pointing to accelerating top-line growth through 2026.
Ahmad also emphasizes the expanding contribution from non-CF assets such as Journavx and Casgevy, which are expected to deliver meaningful revenue gains as patient uptake increases. In addition, she notes the promising late-stage pipeline in rare kidney disease, including povetacicept and inaxaplin, which could unlock new, sizeable markets and supports a premium valuation relative to the current share price and her $598 price objective.
According to TipRanks, Ahmad is a 4-star analyst with an average return of 2.5% and a 51.77% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Regeneron, Gilead Sciences, and Vertex Pharmaceuticals.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $612.00 price target.